In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis
- PMID: 12149337
- PMCID: PMC120660
- DOI: 10.1128/JCM.40.8.2828-2831.2002
In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis
Abstract
In vitro, terbinafine is highly active against a broad spectrum of pathogenic fungi. We evaluated the activities of terbinafine and itraconazole against 31 isolates of Paracoccidioides brasiliensis. The tests were conducted by using a broth macrodilution procedure. MICs, in micrograms per milliliter, were as follows: terbinafine, 0.015 to 1.0 (geometric mean, 0.1188); itraconazole, 0.007 to 0.5 (geometric mean, 0.03165). The usual therapy for paracoccidioidomycosis is sulfonamides, amphotericin B, and azole derivatives (ketoconazole, itraconazole, and fluconazole). In comparison to amphotericin B, azole derivatives allow shorter treatment courses, can be administered orally, and are equally effective. Itraconazole has as high efficacy as ketoconazole, but with superior tolerance. It is the current drug of choice for treatment of paracoccidioidomycosis. The data obtained in this study indicate that terbinafine is active against P. brasiliensis in vitro and suggest that this allylamine can be considered a new option as drug therapy for paracoccidioidomycosis.
Similar articles
-
[In vitro sensitivity of Paracoccidioides brasiliensis to systemically used antifungal agents].Rev Argent Microbiol. 1999 Apr-Jun;31(2):78-81. Rev Argent Microbiol. 1999. PMID: 10425663 Spanish.
-
In vitro susceptibilities of Paracoccidioides brasiliensis yeast form to antifungal drugs.Mycoses. 2000;43(11-12):403-7. Mycoses. 2000. PMID: 11204357
-
In vitro comparison of terbinafine and itraconazole against Penicillium marneffei.Antimicrob Agents Chemother. 2000 May;44(5):1407-8. doi: 10.1128/AAC.44.5.1407-1408.2000. Antimicrob Agents Chemother. 2000. PMID: 10770792 Free PMC article.
-
Oral therapeutic agents in fungal nail disease.J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S78-81. doi: 10.1016/s0190-9622(08)81274-1. J Am Acad Dermatol. 1994. PMID: 8077514 Review.
-
Antifungal chemotherapy.Prog Drug Res. 1995;44:87-127. doi: 10.1007/978-3-0348-7161-7_3. Prog Drug Res. 1995. PMID: 7644668 Review. No abstract available.
Cited by
-
Paracoccidioidomycosis: Current Status and Future Trends.Clin Microbiol Rev. 2022 Dec 21;35(4):e0023321. doi: 10.1128/cmr.00233-21. Epub 2022 Sep 8. Clin Microbiol Rev. 2022. PMID: 36074014 Free PMC article. Review.
-
PARACOCCIDIOIDOMYCOSIS TREATMENT.Rev Inst Med Trop Sao Paulo. 2015 Sep;57 Suppl 19(Suppl 19):31-7. doi: 10.1590/S0036-46652015000700007. Rev Inst Med Trop Sao Paulo. 2015. PMID: 26465367 Free PMC article. Review.
-
Influence of different media, incubation times, and temperatures for determining the MICs of seven antifungal agents against Paracoccidioides brasiliensis by microdilution.J Clin Microbiol. 2013 Feb;51(2):436-43. doi: 10.1128/JCM.02231-12. Epub 2012 Nov 21. J Clin Microbiol. 2013. PMID: 23175254 Free PMC article.
-
In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.J Clin Microbiol. 2004 Sep;42(9):4319-20. doi: 10.1128/JCM.42.9.4319-4320.2004. J Clin Microbiol. 2004. PMID: 15365033 Free PMC article.
-
Paracoccidioidomycosis due to Paracoccidioides brasiliensis S1 plus HIV co-infection.Mem Inst Oswaldo Cruz. 2018 Mar;113(3):167-172. doi: 10.1590/0074-02760170310. Mem Inst Oswaldo Cruz. 2018. PMID: 29412355 Free PMC article.
References
-
- Ellis, D. H. 1998. The potential for terbinafine in non-dermatophyte fungal infections with or without skin involvement. J. Dermatol. Treat. 9(Suppl. 1):S35-S38.
-
- Espinel-Ingroff, A., M. Pfaller, M. E. Erwin, and R. N. Jones. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J. Clin. Microbiol. 34:848-852. - PMC - PubMed
-
- Fava Netto, C. 1955. Estudos quantitativos sobre a fixação do complemento na blastomicose Sul Americana com antígeno polissacarídico. Arq. Cir. Clin. Exp. 18:197-254. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources